nach oben

Erschienen in:

01.02.2016 | Clinical Trial Report

Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study

verfasst von: Miriam König, Cornelia von Hagens, Sebastian Hoth, Ingo Baumann, Ingeborg Walter-Sack, Lutz Edler, Serkan Sertel

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Artesunate (ART) has been used for a long time in the treatment of Plasmodium falciparum malaria and has been considered safe. The present phase I study aimed to determine the daily dose of ART that is well tolerated as add-on therapy in patients with breast cancer for 4 weeks of therapy. Ototoxicity could be a potential safety concern in settings different from malaria. Therefore, comprehensive audiological assessment was essential.

Methods

The ARTIC M33/2 study was a prospective, open, uncontrolled, monocentric phase I dose-escalation study to evaluate the safety and tolerability of ART in patients with advanced breast cancer. Patients received either 100, 150 or 200 mg oral ART daily for a test phase of 4 weeks as add-on therapy to their ongoing oncological treatment. For the investigation of the safety of ART for hearing, an audiological assessment was performed with each patient before the intake of ART and after 4 weeks of therapy.

Results

Twenty-three female patients were included in the study. During the test phase, four patients had adverse events (AEs) of the auditory system possibly related to the intake of ART. However, none of these AEs was classified as severe AE (SAE) and did not require treatment interruption. Four patients had AEs concerning the vestibular system (vertigo) during the test phase, one of which was classified as SAE. However, the SAE was fully reversible after discontinuation of ART.

Conclusion

None of the audiological results after 4 weeks of therapy with ART showed any dose-limiting auditory toxicity. However, audiological monitoring in further clinical studies with prolonged use of oral ART in doses up to 200 mg daily is warranted.

The ARTIC M33/2 study is registered at eudract.ema.europa.eu with the Number 2007-004432-23 and at clinicaltrials.gov with the Number NCT00764036.

This use of the tool BN20+ as screening instrument for frequent screening for safety monitoring was permitted by the EORTC.

Davis TM, Karunajeewa HA, Ilett KF (2005) Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust 182(4):181–185PubMed

World Health Organization (2006) Guidelines for the treatment of malaria. World Health Organization, Geneva

Sun WC, Han JX, Yang WY, Deng DA, Yue XF (1992) Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro. Zhongguo Yao Li Xue Bao 13(6):541–543PubMed

Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18(4):767–773PubMed

Li Y, Shan F, Wu JM, Wu GS, Ding J, Xiao D, Yang WY, Atassi G, Leonce S, Caignard DH, Renard P (2001) Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg Med Chem Lett 11(1):5–8CrossRefPubMed

Singh NP, Lai H (2001) Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70(1):49–56CrossRefPubMed

Reungpatthanaphong P, Mankhetkorn S (2002) Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 25(12):1555–1561CrossRefPubMed

Disbrow GL, Baege AC, Kierpiec KA, Yuan H, Centeno JA, Thibodeaux CA, Hartmann D, Schlegel R (2005) Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 65(23):10854–10861. doi:10.1158/0008-5472.CAN-05-1216 CrossRefPubMed

Chen HH, Zhou HJ, Wang WQ, Wu GD (2004) Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol 53(5):423–432. doi:10.1007/s00280-003-0751-4 CrossRefPubMed

10.

Dell’Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, Efferth T (2004) Inhibition of angiogenesis in vivo and growth of Kaposi’s sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 68(12):2359–2366. doi:10.1016/j.bcp.2004.08.021 CrossRefPubMed

11.

Moore JC, Lai H, Li JR, Ren RL, McDougall JA, Singh NP, Chou CK (1995) Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 98(1):83–87CrossRefPubMed

12.

Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G (2005) Artesunate in the treatment of metastatic uveal melanoma–first experiences. Oncol Rep 14(6):1599–1603PubMed

13.

Singh NP, Verma KB (2002) Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol 10(4):279–280CrossRef

14.

Genovese RF, Newman DB, Brewer TG (2000) Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol Biochem Behav 67(1):37–44CrossRefPubMed

15.

Genovese RF, Newman DB, Li Q, Peggins JO, Brewer TG (1998) Dose-dependent brainstem neuropathology following repeated arteether administration in rats. Brain Res Bull 45(2):199–202CrossRefPubMed

16.

Kissinger E, Hien TT, Hung NT, Nam ND, Tuyen NL, Dinh BV, Mann C, Phu NH, Loc PP, Simpson JA, White NJ, Farrar JJ (2000) Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients. Am J Trop Med Hyg 63(1–2):48–55PubMed

17.

Van Vugt M, Angus BJ, Price RN, Mann C, Simpson JA, Poletto C, Htoo SE, Looareesuwan S, White NJ, Nosten F (2000) A case–control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 62(1):65–69PubMed

18.

McCall MB, Beynon AJ, Mylanus EA, van der Ven AJ, Sauerwein RW (2006) No hearing loss associated with the use of artemether–lumefantrine to treat experimental human malaria. Trans R Soc Trop Med Hyg 100(12):1098–1104. doi:10.1016/j.trstmh.2006.02.017 CrossRefPubMed

19.

Toovey S, Jamieson A (2004) Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 98(5):261–267; discussion 268-269. doi:10.1016/j.trstmh.2003.11.001

20.

Mehta U, Barnes KI, Kathard H, Vugt M, Durrheim D (2005) Comment on: audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 99(4):313–314; author reply 314-315. doi:10.1016/j.trstmh.2004.11.006

21.

Hutagalung R, Htoo H, Nwee P, Arunkamomkiri J, Zwang J, Carrara VI, Ashley E, Singhasivanon P, White NJ, Nosten F (2006) A case–control auditory evaluation of patients treated with artemether–lumefantrine. Am J Trop Med Hyg 74(2):211–214PubMed

22.

Reinhart H, Hughson C, de Palacios PI (2005) Comment on: audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 99(4):315–316; author reply 316-317. doi:10.1016/j.trstmh.2004.11.008

23.

Panossian LA, Garga NI, Pelletier D (2005) Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann Neurol 58(5):812–813. doi:10.1002/ana.20620 CrossRefPubMed

24.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Dehaes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European-Organization-for-Research-and-Treatment-of-Cancer Qlq-C30—a quality-of-life instrument for use in international clinical-trials in oncology. J Natl Cancer I 85(5):365–376. doi:10.1093/jnci/85.5.365 CrossRef

25.

Sertel S, Eichhorn T, Sieber S, Sauer A, Weiss J, Plinkert PK, Efferth T (2010) Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem Biol Interact 185(1):42–52. doi:10.1016/j.cbi.2010.02.002 CrossRefPubMed

26.

Sertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW, Efferth T (2010) Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules 15(4):2886–2910. doi:10.3390/molecules15042886 CrossRefPubMed

27.

Krishna S, Bustamante L, Haynes RK, Staines HM (2008) Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29(10):520–527. doi:10.1016/j.tips.2008.07.004 CrossRefPubMedPubMedCentral

28.

Firestone GL, Sundar SN (2009) Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 11:e32. doi:10.1017/S1462399409001239 CrossRefPubMed

29.

Krishna S, Ganapathi S, Ster IC, Saeed ME, Cowan M, Finlayson C, Kovacsevics H, Jansen H, Kremsner PG, Efferth T, Kumar D (2015) A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine 2(1):82–90. doi:10.1016/j.ebiom.2014.11.010 CrossRefPubMedPubMedCentral

30.

Carrasquilla G, Baron C, Monsell EM, Cousin M, Walter V, Lefevre G, Sander O, Fisher LM (2012) Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether–lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 86(1):75–83. doi:10.4269/ajtmh.2012.11-0192 CrossRefPubMedPubMedCentral

31.

Carrara VI, Phyo AP, Nwee P, Soe M, Htoo H, Arunkamomkiri J, Singhasivanon P, Nosten F (2008) Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand. Malar J 7:233. doi:10.1186/1475-2875-7-233 CrossRefPubMedPubMedCentral

32.

Gurkov R, Eshetu T, Miranda IB, Berens-Riha N, Mamo Y, Girma T, Krause E, Schmidt M, Hempel JM, Loscher T (2008) Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J 7:179. doi:10.1186/1475-2875-7-179 CrossRefPubMedPubMedCentral

33.

Schmutzhard J, Kositz CH, Lackner P, Dietmann A, Fischer M, Glueckert R, Reindl M, Stephan K, Riechelmann H, Schrott-Fischer A, Schmutzhard E (2010) Murine malaria is associated with significant hearing impairment. Malar J 9:159. doi:10.1186/1475-2875-9-159 CrossRefPubMedPubMedCentral

34.

Adjei GO, Goka BQ, Kitcher E, Rodrigues OP, Badoe E, Kurtzhals JA (2013) Reversible audiometric threshold changes in children with uncomplicated malaria. J Trop Med 2013:360540. doi:10.1155/2013/360540 CrossRefPubMedPubMedCentral

Titel: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study
verfasst von: Miriam König
Cornelia von Hagens
Sebastian Hoth
Ingo Baumann
Ingeborg Walter-Sack
Lutz Edler
Serkan Sertel
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-2960-7

Springer Medizin

Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study